A potentially groundbreaking development has emerged in the ongoing search for effective PTSD remedies. Two leading pharmaceutical companies have recently submitted a supplemental new drug application to the FDA for a treatment regimen that shows promise. At Serene Behavioral Health, we keep our community informed about the latest advancements in mental health treatment, and this new development is particularly noteworthy.

A Combination Approach to Treating PTSD

The innovative treatment regimen combines brexpiprazole, commercially known as Rexulti, with an SSRI medication called sertraline. Brexpiprazole is an antipsychotic agent that alters brain chemicals; it is currently FDA-approved for treating conditions such as schizophrenia, major depressive disorder, and agitation associated with Alzheimer’s disease and other forms of dementia. Meanwhile, sertraline is an antidepressant that doctors also prescribe to treat anxiety disorders.

Substantial clinical data back the proposal for this new PTSD treatment. The two trials, which form part of one of the largest clinical development programs ever conducted for PTSD, have shown promising results. The combination of brexpiprazole and sertraline demonstrated statistical superiority in treating PTSD symptoms compared to sertraline paired with a placebo, suggesting that the addition of brexpiprazole could significantly enhance the effectiveness of PTSD treatment regimens.

The Impact of Brexpiprazole on PTSD

Brexpiprazole offers new hope for many people living with the complexities of PTSD. This drug could provide a more robust defense against intrusive symptoms like severe anxiety, flashbacks and emotional distress by potentially modifying the brain pathways associated with stress and trauma responses.

As we await the FDA’s decision on this new drug application, our clinicians will stay informed about the potential changes and advancements in PTSD treatment. At Serene Behavioral Health, we continue to monitor these developments closely to provide our clients with the most effective and innovative treatment options.

The possible U.S. government approval of brexpiprazole plus sertraline for PTSD represents a significant advance in our ability to manage a condition that affects millions. This development underscores the importance of continual research and innovation in mental health. For people who struggle with PTSD, advancements like these offer hope for a more stable and fulfilling life.

Stay tuned to our blog for more updates on this promising treatment option as we follow its progress toward potential FDA approval. Innovation is ongoing, and each new discovery moves us closer to understanding and managing mental health more effectively. You deserve to live a life free from trauma’s severe effects. Contact us today for more information about our proven therapeutic models and compassionate trauma therapists.